Featured Products:

Featured Articles:

Highlights:

News:

Events:

PROTON PUMP INHIBITORS

PROTON PUMP INHIBITORS: INTRODUCTION

Inhibition of the Proton Pump in the parietal cells has been established as the major therapeutic category in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux.

Proton pump inhibitors are known to act by accumulating in the target cell and are activated by acid and bind strongly to the specific target- the proton pump.

The clinical superiority of the proton pump inhibitors is due to their high efficacy and long duration of the acid inhibition in comparison with other antisecretory drugs.Carbapenems can be grouped as (2),

Omeprazole is the very first proton pump inhibitor which was introduced in 1989; later Lansoprazole, Rabeprazole, Pantoprazole, and Esomeprazole were introduced.

Omeprazole, Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole are characterized as gastric acid pump inhibitors, in that they block the final step of acid production. Wherein Pantoprazole acts by forming a covalent bond to two sites of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. The inhibitory effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

Omeprazole, Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole, all belong to the antisecretory class of drugs and are chemically substituted benzimidazoles, where in Esomeprazole is the true S- isomer of Omeprazole.(4)

CLINICAL INDICATION FOR PROTON PUMP INHIBITORS

Omeprazole:

Indication:
  • Treatment of gastric ulcer (GU), erosive esophagitis (EE), and gastroesophageal reflux disease (GERD) with or without esophageal lesion.
  • Maintenance therapy of EE.
  • Eradication of Helicobacter pylori in triple therapy with clarithromycin and amoxicillin or in double therapy with clarithromycin only.
Lansoprazole:

Indication:
  • Treatment of duodenal ulcer (DU), both H. pylori positive and negative, active benign GU, GERD, EE and pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES).
  • Maintenance therapy of DU and EE.
  • Eradication of H. pylori in triple therapy with clarithromycin and amoxicillin, or in double therapy with amoxicillin only.
Rabeprazole:

Indication:
  • Treatment of erosive or ulcerative GERD, DU and hypersecretory syndromes including ZES.
  • Maintenance of erosive or ulcerative GERD.
Pantoprazole:

Indication:
  • Treatment of EE (erosive esophagitis) associated with GERD (gastroesophageal reflux disease).
Esomeprazole:

Indication:
  • In the treatment of GERD, healing of EE, maintenance of healing of EE, H. pylori Eradication to reduce the risk of duodenal ulcer recurrence in triple therapy with clarithromycin and amoxicillin.
SRS Pharmaceutical supplies the following Proton Pump Inhibitors:

Omeprazole as:
OmeprazoleCapsules20mg, 40mgStrip, Blister10's
OmeprazoleLyophilised Injection40mgVial10ml Vial
Omeprazole Sodium with Sodium BicarbonateTablets20mg, 40mgBlister10's
Lansoprazole as:
LansaprazoleCapsules30mgStrip10's
Rabeprazole as:
Rabeprazole Tablets10mg, 20mgBlister10's, 15's
Rabeprazole Sodium with Sodium BicarbonateTablets10mg, 20mgBlister10's, 15's
Pantoprazole as:
PantoprazoleTablets20mg, 40mgBlister10's
Pantoprazole Lyophilised Injection 40mgVial1's


Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. Please see your health care professional for more information about your specific medical condition and the use of the above mentioned drug.
  TOP
 
     
  Home | About Us | Global Presence | Healthcare Products | Q & C | Manufacturing | Group Of Companies | News | Career | Contact Us  
 
  Copyright © 1995-2010 SRS PHARMACEUTICALS PVT. LTD. Website Design and Developed by Miracleworx Web Solutions Pvt. Ltd.  |  Sitemap